Clinical Trial Update: A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP) [Phase 2]

View source ↗

Summary

This Phase 2 study (LEAP) compared CO-1.01 with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma. The trial results were posted in 201…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• CO-1.01
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Clovis Oncology, Inc. | Conditions: Metastatic Pancreatic Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2014-04-17